↓ Skip to main content

Dove Medical Press

Article Metrics

Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, May 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
55 Mendeley
Title
Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study
Published in
International Journal of Chronic Obstructive Pulmonary Disease, May 2017
DOI 10.2147/copd.s128750
Pubmed ID
Authors

Cheong-Ju Kim, Hyoung Kyu Yoon, Myung-Jae Park, Kwang-Ha Yoo, Ki-Suck Jung, Jeong-Woong Park, Seong Yong Lim, Jae Jeong Shim, Yong Chul Lee, Young-Sam Kim, Yeon-Mok Oh, Song Kim, Chul-Gyu Yoo

Abstract

Pulmonary tuberculosis (TB) is a risk factor for chronic obstructive pulmonary disease (COPD); however, few clinical studies have investigated treatment effectiveness in COPD patients with destroyed lung by TB. The Indacaterol effectiveness in COPD patients with Tuberculosis history (INFINITY) study assessed the efficacy and safety of once-daily inhaled indacaterol 150 µg for the treatment of Korean COPD patients with destroyed lung by TB and moderate-to-severe airflow limitation. This was a multicenter, double-blind, parallel-group study, in which eligible patients were randomized (1:1) to receive either once-daily indacaterol 150 µg or placebo for 8 weeks. The primary efficacy endpoint was change from baseline in trough forced expiratory volume in 1 s at Week 8; the secondary endpoints included changes in transition dyspnea index score and St George's Respiratory Questionnaire for COPD score at Week 8. Safety was evaluated over 8 weeks. Of the 136 patients randomized, 119 (87.5%) completed the study treatment. At Week 8, indacaterol significantly improved trough forced expiratory volume in 1 s versus placebo (treatment difference [TD] 140 mL, P<0.001). Statistically significant improvement in transition dyspnea index score (TD =0.78, P<0.05) and numerical improvement in St George's Respiratory Questionnaire for COPD score (TD =-2.36, P=0.3563) were observed with indacaterol versus placebo at Week 8. Incidence of adverse events was comparable between the treatment groups. Indacaterol provided significantly superior bronchodilation, significant improvement in breathlessness and improved health status with comparable safety versus placebo in Korean COPD patients with destroyed lung by TB and moderate-to-severe airflow limitation.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 55 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 18%
Student > Master 10 18%
Other 3 5%
Student > Postgraduate 3 5%
Researcher 3 5%
Other 5 9%
Unknown 21 38%
Readers by discipline Count As %
Medicine and Dentistry 10 18%
Nursing and Health Professions 8 15%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Computer Science 2 4%
Materials Science 2 4%
Other 6 11%
Unknown 24 44%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 April 2018.
All research outputs
#11,105,037
of 18,910,941 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#1,096
of 2,081 outputs
Outputs of similar age
#135,708
of 278,180 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#34
of 63 outputs
Altmetric has tracked 18,910,941 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,081 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,180 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 63 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.